This hormone tells the body to release insulin when blood glucose (sugar) levels rise and suppresses more glucose from being released into the blood
Good choice during the 0.25mg starting dose phase
While skin biopsy is unparalleled for small-fiber evaluation, current guidelines recommend integrating it with nerve conduction studies and clinical examination for comprehensive neuropathy assessment [41]
Placebo-adjusted outcomes of time in range, time in hypoglycemia, insulin use and carbohydrate intake were all comparable to what we observed with our research-based AID
These changes were statistically significant, and the direction of effect suggests possible neuroprotection, but the magnitude was very small (particularly if we compare these results to those in the Phase 3 trials of AD drugs that are now approved, such as lecanemab or donanemab) , the sample limited, and there is no evidence these shifts translate into meaningful clinical benefit